|
|
11080 Circlepoint Road, Suite 200
Westminster, CO 80020 USA
phone:303.426.6262
fax:303.426.4731
|
|
| Symbol |
ALTH |
| Exchange |
Nasdaq |
| Founded |
0 |
| Employees |
85 |
|
|
| www.allos.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Biotechnology company for anti-cancer therapeutics |
|
| Management |
| pralatrexate, Paul L. Berns, President and Chief Executive Officer; Bruce K. Bennett, Vice President, Pharmaceutical Operations; James V. Caruso, Executive Vice President, Chief Commercial Officer; David C. Clark Vice President, Finance and Treasurer; Marc H. Graboyes Senior Vice President, General Counsel |
| |
|
|
|
|
|
|
|
| Keywords |
| therapies, pralatrexate, lymphoma, biopharmaceutical, cancer, folate analogue metabolic inhibitor |
|
|
|
| Description |
|
Allos Therapeutics is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing FOLOTYN in other potential indications. Allos retains exclusive worldwide rights to FOLOTYN for all indications. The company is headquartered in Westminster, Colorado. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
